Enveric Biosciences (ENVB) Accounts Payables (2010 - 2026)
Enveric Biosciences (ENVB) posted Accounts Payables of $280315.0 for Q1 2026, down 51.75% sequentially from $581020.0 in Q4 2025, and down 58.11% YoY from $669194.0 in Q1 2025.
Enveric Biosciences (ENVB) Accounts Payables (2010 - 2026) Analysis & Trends
Enveric Biosciences has reported Accounts Payables for 17 years, with the latest figure at $280315.0 in Q1 2026.
- Quarterly Accounts Payables fell 58.11% year-over-year to $280315.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $280315.0 (down 58.11% YoY) and the FY2025 annual result came in at $581020.0, up 11.36% from the prior year.
- Accounts Payables eased to $280315.0 in Q1 2026 per ENVB's latest filing, from $581020.0 in the prior quarter.
- Over five years, Accounts Payables peaked at $1.9 million in Q1 2024 and troughed at $280315.0 in Q1 2026.
- A 5-year average of $871147.2 and a median of $697010.5 in 2022 frame the typical range for Accounts Payables.
- The sharpest annual moves came in 2022 and 2023: Accounts Payables sank 67.16% in 2022, then surged 163.08% in 2023.
- Over 5 years, Accounts Payables stood at $463275.0 in 2022, then soared by 163.08% to $1.2 million in 2023, then sank by 57.19% to $521747.0 in 2024, then climbed by 11.36% to $581020.0 in 2025, then plunged by 51.75% to $280315.0 in 2026.
- According to Business Quant data, Accounts Payables over the past three periods registered $280315.0, $581020.0, and $683707.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Enveric Biosciences | 5.66 Mn | -2.64 Mn | - | 682,794.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 280,315.00 |
| Dec 31, 2025 | 581,020.00 |
| Sep 30, 2025 | 683,707.00 |
| Jun 30, 2025 | 1.04 Mn |
| Mar 31, 2025 | 669,194.00 |
| Dec 31, 2024 | 521,747.00 |
| Sep 30, 2024 | 576,324.00 |
| Jun 30, 2024 | 459,898.00 |
| Mar 31, 2024 | 1.85 Mn |
| Dec 31, 2023 | 1.22 Mn |
| Sep 30, 2023 | 1.10 Mn |
| Jun 30, 2023 | 1.23 Mn |
| Mar 31, 2023 | 1.79 Mn |
| Dec 31, 2022 | 463,275.00 |
| Sep 30, 2022 | 710,314.00 |
| Jun 30, 2022 | 754,296.00 |
| Dec 31, 2021 | 683,393.00 |
| Sep 30, 2021 | 2.16 Mn |
| Jun 30, 2021 | 1.02 Mn |
| Mar 31, 2021 | 626,947.00 |